Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Blood

• Publication date

  2003-04-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2002-10-3092PMID 12468425
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Virus-based vectors for human vaccine applications.

  2002cited by this paper
• Immunotherapy to reconstitute immunity to DNA viruses.

  2002cited by this paper
• The number of long‐lasting functional memory CD8+ T cells generated depends on the nature of the initial nonspecific stimulation

  2002cited by this paper
• Approach to Hodgkin's lymphoma in the new millennium

  2002cited by this paper
• MVA: a cuckoo in the vaccine nest?

  2001cited by this paper
• Immunotherapeutic strategies for EBV-associated malignancies.

  2001cited by this paper
• Cost-Efficient Quantification of Enzyme-Linked Immunospot

  2001cited by this paper
• Cost-efficient quantification of enzyme-linked immunospot.

  2001cited by this paper
• Genetic vaccination for the active immunotherapy of cancer.

  2001cited by this paper
• Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas.

  2000cited by this paper
• Hodgkin disease: prognostic factors and treatment strategies

  2000cited by this paper
• The prime-boost strategy: exciting prospects for improved vaccination.

  2000cited by this paper
• EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design.

  1999cited by this paper
• Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.

  1998cited by this paper
• Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division.

  1998cited by this paper
• Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.

  1998cited by this paper
• Tumour surveillance: Missing peptides and MHC molecules

  1998cited by this paper
• Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Hodgkin Disease. Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas

  1998cited by this paper
• Differential immunogenicity of Epstein-Barr virus (EBV) encoded growth transformation-associated antigens in a murine model system.

  1997cited by this paper
• Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes

  1997cited by this paper
• Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

  1997cited by this paper
• Quantification of antigen specific CD8+ T cells using an ELISPOT assay.

  1995cited by this paper
• Immunol. Cell Biol.

  1995cited by this paper
• Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design.

  1995cited by this paper
• Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue.

  1994cited by this paper
• Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

  1992cited by this paper
• Copyright � 1995, American Society for Microbiology Immune Regulation in Epstein-Barr Virus-Associated Diseases

  year unknowncited by this paper

• Designing multifunctional recombinant vaccines: an engineering strategy based on innovative epitope prediction-guided splicing

  2025cites this paper
• The Role of Epstein–Barr Virus Molecular Mimicry in Various Autoimmune Diseases

  2025cites this paper
• Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

  2024cites this paper
• Coinfection of EBV with other pathogens: a narrative review

  2024cites this paper
• Advances, opportunities and challenges in developing therapeutic cancer vaccines.

  2023cites this paper
• Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice

  2023cites this paper
• Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

  2022cites this paper
• Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein–Barr Virus-Associated Malignancies

  2022cites this paper
• Vaccination as a therapeutic strategy for Nasopharyngeal carcinoma.

  2022cites this paper
• The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy

  2021cites this paper
• Cancer Vaccines: Antigen Selection Strategy

  2021cites this paper
• Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction

  2021cites this paper
• The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development

  2021cites this paper
• Dynamic changes in plasma Epstein–Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study

  2018cites this paper
• A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy

  2018influential citation
• Contribution of Epstein–Barr Virus Latent Proteins to the Pathogenesis of Classical Hodgkin Lymphoma

  2018cites this paper
• Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo

  2017cites this paper
• Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities

  2017cites this paper
• Functional characterisation of tumour-specific T cell responses in pancreatic cancer

  2017cites this paper
• The Use of Rabbit Model for the Efficacy of a Novel Epstein-Barr virus (EBV) Peptide Vaccine

  2016cites this paper
• The other side of the coin: Leveraging Epstein–Barr virus in research and therapy

  2016influential citation
• Clinical trials in nasopharyngeal carcinoma-past, present and future.

  2016cites this paper
• Management of comorbid advanced stage gingival squamous cell carcinoma and classical Hodgkin lymphoma by a combination of surgery and split ABVD chemotherapy

  2015cites this paper
• The Epstein–Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development

  2015cites this paper
• The Development of Prophylactic and Therapeutic EBV Vaccines.

  2015cites this paper
• Latent membrane protein 1 and the B lymphocyte-a complex relationship.

  2014cites this paper
• Therapeutic implications of Epstein–Barr virus infection for the treatment of nasopharyngeal carcinoma

  2014cites this paper
• Epstein-Barr Virus (EBV): Infectious Mononucleosis and Other Non-malignant EBV-Associated Diseases

  2014cites this paper
• Advances and Prospects in Cancer Immunotherapy

  2014cites this paper
• The Evolving Role of Systemic Therapy in Nasopharyngeal Carcinoma: Current Strategies and Perspectives

  2013cites this paper
• Emerging treatment options for nasopharyngeal carcinoma

  2013cites this paper
• 47 – Epstein-Barr virus vaccines

  2013cites this paper
• Nasopharyngeal Carcinoma

  2013cites this paper
• Nasopharyngeal Carcinoma Immunotherapy: Current Strategies and Perspectives

  2013cites this paper
• The biological basis and clinical correlates of the association between EBV-positive Hodgkin lymphoma and HLA class I

  2013cites this paper
• A mechanistic analysis of DNA vaccine-induced tumor immunity against the viral oncoprotein simian virus 40 large tumor antigen

  2012cites this paper
• Generating DNA sequences encoding tandem peptide repeats suitable for expression and immunological application

  2012cites this paper
• An Epstein-Barr Virus Mutant Produces Immunogenic Defective Particles Devoid of Viral DNA

  2012cites this paper
• Associated with the Epstein-Barr Virus

  2012cites this paper
• Vaccines and Antiviral Drugs for Diseases Associated with the Epstein-Barr Virus

  2012cites this paper
• Recent Advances in Nasopharyngeal Carcinoma Research and its Pathogenesis

  2012cites this paper
• Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs

  2011cites this paper
• Presencia del virus de Epstein-Barr en la esclerosis múltiple

  2011cites this paper
• Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies

  2011cites this paper
• Mice with human immune system components as in vivo models for infections with human pathogens

  2011cites this paper
• Identification of Two Novel HLA-A*0201-Restricted CTL Epitopes Derived from MAGE-A4

  2011cites this paper
• Diagnostic and Protective Aspects of Humoral Immune Responses to Epstein-Barr Virus Encoded Proteins in Nasopharyngeal Carcinoma

  2010cites this paper
• Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes

  2010cites this paper
• CHAPTER 8 OK.cdr

  2010cites this paper
• Immunoinformatics: The Next Step in Vaccine Design

  2010cites this paper
• Epstein Barr virus latent membrane protein-1 (LMP-1) expression and angiogenesis in Indonesian nasopharyngeal carcinoma (NPC)

  2010cites this paper
• Epstein–Barr virus: novel patented therapeutics

  2010cites this paper
• Vaccines and Immunotherapeutics for the Treatment of Malignant Disease

  2010cites this paper
• New strategies and patent therapeutics in EBV-associated diseases.

  2010cites this paper
• Treatment approaches to nasopharyngeal carcinoma: a review

  2010cites this paper
• Epstein-Barr virus infection in the Edinburgh student population

  2009cites this paper
• Expression modes and clinical manifestations of latent membrane protein 1, Ki‐67, cyclin‐B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinoma

  2009cites this paper
• EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.

  2009cites this paper
• Epstein-Barr virus and carcinogenesis: beyond Burkitt's lymphoma.

  2009cites this paper
• Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma

  2009cites this paper
• Optimization of LMP‐specific CTL expansion for potential adoptive immunotherapy in NPC patients

  2009cites this paper
• Vaccines under study: non‐HIV vaccines

  2009cites this paper
• Construction and humoral immune response of Epstein-Barr virus latent membrane protein 2 DNA vaccine in mice

  2009cites this paper
• Drug development for recurrent and refractory classical Hodgkin lymphoma

  2009cites this paper
• Novel Approach to the Formulation of an Epstein-Barr Virus Antigen-Based Nasopharyngeal Carcinoma Vaccine

  2009cites this paper
• Einfluss der Immunsuppressiven Medikation auf die Epstein-Barr Viruslast bei Kindern nach Herztransplantation

  2009cites this paper
• Adoptive cellular therapy with T cells specific for EBV-derived tumor antigens.

  2008cites this paper
• A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus.

  2008cites this paper
• Novel virally targeted therapies of EBV-associated tumors.

  2008cites this paper
• Immune escape by Epstein-Barr virus associated malignancies.

  2008cites this paper
• Molecular Pathogenesis and Targeted Therapy of Hepatocellular Carcinoma

  2008cites this paper
• Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.

  2008cites this paper
• Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.

  2008cites this paper
• Regulation and dysregulation of Epstein–Barr virus latency: Implications for the development of autoimmune diseases

  2008cites this paper
• Regulatory T cells as therapeutic target in Hodgkin's lymphoma.

  2008cites this paper
• Adoptive cell therapy against EBV-related malignancies: a survey of clinical results.

  2008cites this paper
• Immunotherapies for Hodgkin's lymphoma.

  2008cites this paper
• Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

  2008cites this paper
• [Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine].

  2008cites this paper
• Generating functional CD8+ T cell memory response under transient CD4+ T cell deficiency: Implications for vaccination of immunocompromised individuals

  2008cites this paper
• Mononucleosis infecciosa en pacientes con enfermedad inflamatoria intestinal en tratamiento con azatioprina

  2008cites this paper
• Adoptive cell therapy against EBV-related malignancies: a survey of clinical results

  2008cites this paper
• Regulatory T cells as therapeutic target in Hodgkin's lymphoma

  2008cites this paper
• Enhancing immune responses for cancer therapy.

  2007cites this paper
• Efectos de la infección viral en el paciente trasplantado

  2007cites this paper
• Improving T cell therapy for cancer.

  2007cites this paper
• Relapsed and refractory Hodgkin's lymphoma: new avenues?

  2007cites this paper
• General introduction and scope of the thesis

  2007cites this paper
• Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.

  2007cites this paper
• and early detection of posttransplant lymphoproliferative disorder after solid organ transplantation

  2007cites this paper
• Presentation and early detection of post‐transplant lymphoproliferative disorder after solid organ transplantation

  2007cites this paper
• Epstein‐Barr virus (EBV) latent membrane protein‐1‐specific cytotoxic T lymphocytes targeting EBV‐carrying natural killer cell malignancies

  2006cites this paper
• Epstein–Barr virus: The future for screening, treatment and monitoring of nasopharyngeal carcinoma

  2006cites this paper
• Tumor regression by expression of high physiological levels of EBV latent membrane protein 1

  2006cites this paper
• Correlation of T-cell immune response with spontaneous resolution and subsequent relapse of Hodgkin's lymphoma

  2006cites this paper
• Epstein–Barr virus-associated lymphomas

  2006cites this paper
• Contribution of the Epstein–Barr virus to the molecular pathogenesis of Hodgkin lymphoma

  2006cites this paper
• Review of Epstein–Barr virus and post‐transplant lymphoproliferative disorder post‐solid organ transplantation (Review Article)

  2006cites this paper
• Class I T-cell epitope prediction: improvements using a combination of proteasome cleavage, TAP affinity, and MHC binding.

  2006cites this paper
• Lymphoma following In Vitro Stimulation T Cells from Patients with Hodgkin + CD 8 Functional Reversion of Antigen-Specific

  2006cites this paper